Molecular Partners AG (OTCMKTS:MLLCF – Get Rating)’s stock price was down 7.1% during trading on Wednesday . The stock traded as low as $6.59 and last traded at $6.59. Approximately 200 shares were traded during mid-day trading, a decline of 37% from the average daily volume of 317 shares. The stock had previously closed at $7.09.
Molecular Partners Stock Down 7.1 %
The company’s 50 day simple moving average is $5.97 and its 200 day simple moving average is $6.12.
About Molecular Partners
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs.
See Also
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
